In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...

In a cover story for the first issue of TIME France, Angelina Jolie unveiled her double mastectomy surgircal scars over 10 years after she had the procedure, and explained why she decided to share ...

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

Hormone replacement therapy (HRT) does not increase breast cancer risk in BRCA1/BRCA2 carriers, with estrogen-alone formulations showing a lower risk. The study used a matched-pair design to control ...